*Exon 3 mutations included KRAS Q61E, Q61H, Q61K, Q61L, and Q61R. Exon 4 mutations included KRAS A146P, A146T, A146V, and K117N. NRAS mutations included G12A, G12C, G12D, G12F, G12N, G12R, G12S, G12V, G12W, G13C, G13D, G13E, G13R, G13V, Q61E, Q61H, Q61K, Q61L, Q61R, K117N, A146P, A146T, and A146V.4
†This includes samples where information for specific exons and codons were missing while still having overall RAS mutational status.4
‡Estimates of overall survival, based on patients receiving 1L treatment. Other real-world studies of treatment outcomes in KRAS G12C–mutated mCRC have reported mixed results, with some describing poorer prognosis while others describing no difference.2,7
2L, second line; BRAF, proto-oncogene B-Raf; CI, confidence interval; KRAS, Kirsten rat sarcoma; MSI-H, microsatellite instability-high; MT, mutant type; NRAS, neuroblastoma rat sarcoma; OS, overall survival; PFS, progression-free survival; RAS, rat sarcoma; WT, wild type.
References: 1. Patel JN, et al. J Pers Med. 2019;9:3. 2. Fakih M, et al. Oncologist. 2022;27:663-674. 3. Ohishi T, et al. Int J Mol Sci. 2023;24:1702. 4. Peeters M, et al. Eur J Cancer. 2015;51:1704-1713. 5. Biller LH, et al. JAMA. 2021;325:669-685. 6. Cervantes A, et al. Ann Oncol. 2023;34:10-32. 7. Lee JK, et al. Prec Oncol. 2022;6:91.